MaaT Pharma SA (EPA:MAAT)

France flag France · Delayed Price · Currency is EUR
3.840
-0.090 (-2.29%)
Sep 26, 2025, 5:35 PM CET
-2.29%
Market Cap61.84M
Revenue (ttm)3.92M
Net Income (ttm)-31.13M
Shares Out16.11M
EPS (ttm)-2.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume114,259
Average Volume81,935
Open3.900
Previous Close3.930
Day's Range3.700 - 4.040
52-Week Range3.610 - 9.960
Beta-0.07
RSI38.39
Earnings DateSep 16, 2025

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 67
Stock Exchange Euronext Paris
Ticker Symbol MAAT
Full Company Profile

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.

Financial Statements

News

There is no news available yet.